Anaphore, Inc. Names Former GlaxoSmithKline Top Executive Dr. Russell G. Greig as Executive Chairman to Assist in Driving Anaphore's Pipeline of Next Generation Biological Therapies

LA JOLLA, Calif.--(BUSINESS WIRE)--Anaphore, Inc., an innovative developer of next generation biological therapies, today announced that Russell G. Greig, Ph. D., has joined its Board of Directors as Executive Chairman. Dr. Greig brings an extensive background in all aspects of drug discovery and development, business development, and commercial strategy, as well as first-hand experience working with emerging companies in his most recent role as President of SR One. Dr. Greig’s comprehensive pharmaceutical experience will accelerate the translation of Anaphore’s next generation biological therapies, Atrimers™, into medicines of the future.